Ignite Creation Date:
2025-12-25 @ 1:23 AM
Ignite Modification Date:
2026-02-24 @ 1:44 AM
Study NCT ID:
NCT02280993
Status:
UNKNOWN
Last Update Posted:
2018-03-13
First Post:
2014-08-19
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Phase I/II Feasibility Study Combining Brentuximab Vedotin With Second Line Salvage Chemotherapy (DHAP) in Hodgkin Lymphoma Patients
Sponsor:
Marjolein Spiering
Organization: